Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Policy & Acquisitions

Mergers & Acquisitions

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Mergers & Acquisitions

214 stories · every one Fact-Checked
Takeda and the Indonesian Government launch a plasma donation and plasma-derived medicinal products initiative following the grant of a plasma fractionation license.Mergers & AcquisitionsIndonesia Grants Takeda Plasma Fractionation License for PDMP ProductionIndonesia has granted Takeda a plasma fractionation license, enabling the company to launch a national plasma donation pilot and evaluate local manufacturing of plasma-derived medicinal products (PDMPs).14 Jul 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_uxrp0yuxrp0yuxrpMergers & AcquisitionsSino Biopharma Secures China Rights to GSK’s Trelegy and AnoroSino Biopharmaceutical has deepened its alliance with GSK by obtaining commercialization rights for Trelegy Ellipta and Anoro Ellipta in mainland China.11 Jul 2026 · 3 min read
Fact-Checked
A healthcare worker examines a child held by their mother in a Tinduf clinic.Mergers & AcquisitionsSerum Institute, DNDi Advance VIS513 Into Global Phase III Dengue TrialThe Serum Institute of India (SII) and the Drugs for Neglected Diseases initiative (DNDi) have entered a licensing agreement to accelerate global development of VIS513, a promising monoclonal…10 Jul 2026 · 5 min read
Fact-Checked
Teva_Logo_RGBMergers & AcquisitionsTeva Secures Global Rights to Polpharma Biologics’ Proposed Biosimilar to OcrevusTeva has entered an exclusive global licensing agreement with Polpharma Biologics to commercialize a proposed biosimilar to Ocrevus (ocrelizumab).9 Jul 2026 · 3 min read
Fact-Checked
An employee at the site in BerlinMergers & AcquisitionsBayer Launches Clinical Trials Alliance With CU AnschutzBayer announced a strategic alliance with CU Anschutz, UCHealth and Children’s Hospital Colorado to expand clinical trial infrastructure and accelerate development of new therapies.9 Jul 2026 · 3 min read
Fact-Checked
AstraZeneca licenses Zegfrovy (sunvozertinib) from Dizal to expand treatment options for EGFR exon 20 insertion-positive non-small cell lung cancer worldwide.Mergers & AcquisitionsSino Biopharmaceutical Licenses COPD Candidate TQC3721 to AstraZeneca in Up to $2.1 Billion Respiratory DealSino Biopharmaceutical has entered one of 2026’s largest respiratory licensing agreements, granting AstraZeneca exclusive global rights to TQC3721, its late‑stage inhaled dual PDE3/4 inhibitor for COPD.8 Jul 2026 · 3 min read
Fact-Checked
A scientist in protective clothing uses a microscope for research in a laboratory setting.Mergers & AcquisitionsChemomab, Scipher Merge to Advance Nebokitug in Rheumatoid ArthritisChemomab Therapeutics and Scipher Medicine will merge to create Scipher Medicine Corporation, focused on precision medicine in autoimmune disease.8 Jul 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_nbh443nbh443nbh4Mergers & AcquisitionsPraxis Partners with Remagine Labs to Develop Transdermal Patch for Ulixacaltamide in Essential TremorPraxis Precision Medicines has partnered with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide, its investigational therapy for essential tremor.8 Jul 2026 · 3 min read
Fact-Checked
Researchers discussing data in a laboratory setting, wearing safety gear and blue gloves.Mergers & AcquisitionsVertex to Acquire Crinetics for $10 Billion, Adding PALSONIFY and Phase 3 Atumelnant to Rare Endocrine PortfolioVertex Pharmaceuticals has entered a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, valuing the deal at approximately $10.0 billion ($8.8 billion net of…7 Jul 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_8klh0w8klh0w8klhMergers & AcquisitionsAstex Signs Breast Cancer Drug Discovery Deal with GenentechAstex Pharmaceuticals has signed an exclusive global research collaboration and licensing agreement with Genentech to advance a novel small-molecule breast cancer program targeting a key cell-cycle regulator.6 Jul 2026 · 3 min read
Fact-Checked
Rhapsido (remibrutinib) demonstrates sustained 52-week efficacy across three chronic inducible urticaria subtypes in the Phase III RemIND study.Mergers & AcquisitionsNovartis Acquires Myricx Bio to Advance Novel ADC Payload TechnologyNovartis has agreed to acquire UK-based Myricx Bio to expand its next-generation antibody-drug conjugate (ADC) portfolio with a novel N-myristoyltransferase inhibitor (NMTi) payload platform.6 Jul 2026 · 3 min read
Fact-Checked
Newsroom-Photos-Company-1Mergers & AcquisitionsArcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic FibrosisOn July 2, 2026, Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to support the late‑stage development and commercial readiness of ARCT‑032, its investigational inhaled mRNA…3 Jul 2026 · 3 min read
Fact-Checked
Page 8 of 18